Patents by Inventor Galina I. Kovalevskaya
Galina I. Kovalevskaya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9541563Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.Type: GrantFiled: March 28, 2014Date of Patent: January 10, 2017Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: John F. O'Connor, Galina I. Kovalevskaya, Steven Birken
-
Publication number: 20140212897Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.Type: ApplicationFiled: March 28, 2014Publication date: July 31, 2014Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: John F. O'Connor, Galina I. Kovalevskaya, Steven Birken
-
Patent number: 8691585Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.Type: GrantFiled: June 1, 2011Date of Patent: April 8, 2014Assignee: The Trustees of Columbia University in the City of New YorkInventors: John F. O'Connor, Galina I. Kovalevskaya, Steven Birken
-
Publication number: 20110262938Abstract: The present invention provides a method for predicting the likely timing of the onset of menopause for a perimenopausal female subject by determining the amount of hLH?cf in a sample from the subject comprising the steps of: (a) contacting a sample from the subject with an antibody which specifically binds to hLH?cf without substantially cross-reacting with hLH, hLH? or hLH?cf, under conditions permitting formation of a complex between the antibody and hLH?cf; (b) measuring the amount of complex formed, so as to thereby determine the amount of hLH?cf in the sample; and (c) comprising the amount of hLH?cf in the subject's sample determined in step (b) with either (i) the amount determined for known postmenopausal female subject or (ii) the amount determined for a sample from a known premenopausal female subject, wherein an amount of hLH?cf in the sample similar to the amount of hLH?cf in the known postmenopausal sample indicates temporal proximity to the onset of menopause, and an amount of hLH?cf in the samplType: ApplicationFiled: February 1, 2010Publication date: October 27, 2011Inventors: Steven Birken, Yacov Maydelman, Galina I. Kovalevskaya, John F. O'Connor
-
Publication number: 20110256554Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.Type: ApplicationFiled: June 1, 2011Publication date: October 20, 2011Inventors: John F. O'Connor, Galina I. Kovalevskaya, Steven Birken
-
Patent number: 7977104Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.Type: GrantFiled: September 27, 2006Date of Patent: July 12, 2011Assignee: The Trustees of Columbia University in the City of New YorkInventors: John F. O'Connor, Galina I. Kovalevskaya, Steven Birken
-
Patent number: 7655410Abstract: The present invention provides a method for predicting the likely timing of the onset of menopause for a perimenopausal female subject by determining the amount of hLH?cf in a sample from the subject comprising the steps of: (a) contacting a sample from the subject with an antibody which specifically binds to hLH?cf without substantially cross-reacting with hLH, hLH? or hLH?cf, under conditions permitting formation of a complex between the antibody and hLH?cf; (b) measuring the amount of complex formed, so as to thereby determine the amount of hLH?cf in the sample; and (c) comprising the amount of hLH?cf in the subject's sample determined in step (b) with either (i) the amount determined for known postmenopausal female subject or (ii) the amount determined for a sample from a known premenopausal female subject, wherein an amount of hLH?cf in the sample similar to the amount of hLH?cf in the known postmenopausal sample indicates temporal proximity to the onset of menopause, and an amount of hLH?cf in the samplType: GrantFiled: February 10, 2003Date of Patent: February 2, 2010Assignee: The Trustees of Carolina University in the City of New YorkInventors: Steven Birken, Yacov Maydelman, Galina I. Kovalevskaya, John F. O'Connor
-
Patent number: 7399636Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG is a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.Type: GrantFiled: December 31, 2002Date of Patent: July 15, 2008Assignee: The Trustees of Columbia University in the City of New YorkInventors: John F. O'Connor, Galina I. Kovalevskaya, Steven Birken
-
Patent number: 7229781Abstract: The present invention provides methods to quantitate the hLH? core fragment in a sample. The present invention now makes it possible to evaluate the metabolism of hLH in premenopausal, perimenopausal and postmenopausal women and to distinguish between normal and abnormal physiological states.Type: GrantFiled: May 31, 2002Date of Patent: June 12, 2007Assignee: The Trustees of Columbia University in the City of New YorkInventors: Steven Birken, Yacov Maydelman, Galina I. Kovalevskaya, John F. O'Connor
-
Patent number: 7198954Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.Type: GrantFiled: August 1, 2000Date of Patent: April 3, 2007Assignee: The Trustees of Columbia University in the City of New YorkInventors: John F. O'Connor, Galina I. Kovalevskaya, Steven Birken
-
Publication number: 20040058383Abstract: The present invention provides a method for predicting the likely timing of the onset of menopause for a perimenopausal female subject by determining the amount of hLH&bgr;cf in a sample from the subject comprising the steps of: (a) contacting a sample from the subject with an antibody which specifically binds to hLH&bgr;cf without substantially cross-reacting with hLH, hLH&bgr; or hLH&bgr;cf, under conditions permitting formation of a complex between the antibody and hLH&bgr;cf; (b) measuring the amount of complex formed, so as to thereby determine the amount of hLH&bgr;cf in the sample; and (c) comprising the amount of hLH&bgr;cf in the subject's sample determined in step (b) with either (i) the amount determined for known postmenopausal female subject or (ii) the amount determined for a sample from a known premenopausal female subject, wherein an amount of hLH&bgr;cf in the sample similar to the amount of hLH&bgr;cf in the known postmenopausal sample indicates temporal proximity to the onset of menopause,Type: ApplicationFiled: February 10, 2003Publication date: March 25, 2004Inventors: Steven Birken, Yacov Maydelman, Galina I. Kovalevskaya, John F. O'Connor
-
Publication number: 20030124737Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG is a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.Type: ApplicationFiled: December 31, 2002Publication date: July 3, 2003Inventors: John F. O'Connor, Galina I. Kovalevskaya, Steven Birken
-
Publication number: 20030059842Abstract: The present invention provides methods to quantitate the hLH&bgr; core fragment in a sample. The present invention now makes it possible to evaluate the metabolism of hLH in premenopausal, perimenopausal and postmenopausal women and to distinguish between normal and abnormal physiological states.Type: ApplicationFiled: May 30, 2002Publication date: March 27, 2003Inventors: Steven Birken, Yacov Maydelman, Galina I. Kovalevskaya, John F. O'Connor
-
Patent number: 6521416Abstract: The present invention provides a method for predicting the likely timing of the onset of menopause for a perimenopausal female subject by determining the amount of hLH&bgr;cf in a sample from the subject comprising the steps of: (a) contacting a sample from the subject with an antibody which specifically binds to hLH&bgr;cf without substantially cross-reacting with hLH, hLH&bgr; or hLH&bgr;cf, under conditions permitting formation of a complex between the antibody and hLH&bgr;cf; (b) measuring the amount of complex formed, so as to thereby determine the amount of hLH&bgr;cf in the sample; and (c) comprising the amount of hLH&bgr;cf in the subject's sample determined in step (b) with either (i) the amount determined for known postmenopausal female subject or (ii) the amount determined for a sample from a known premenopausal female subject, wherein an amount of hLH&bgr;cf in the sample similar to the amount of hLH&bgr;cf in the known postmenopausal sample indicates temporal proximity to the onset of menopaType: GrantFiled: August 1, 2000Date of Patent: February 18, 2003Assignee: The Trustees of Columbia University in the City of New YorkInventors: Steven Birken, Yacov Maydelman, Galina I. Kovalevskaya, John F. O'Connor
-
Patent number: 6500627Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG is a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.Type: GrantFiled: February 3, 1998Date of Patent: December 31, 2002Assignee: The Trustees of Columbia University in the City of New YorkInventors: John F. O'Connor, Galina I. Kovalevskaya, Steven Birken